Signal Personalized vaccine plus pembrolizumab cut recurrence or death risk by 49% in melanoma

Summary

The chapter's second clinical result is a multicentre trial across the United States and Europe in which high-risk melanoma patients received a personalized vaccine alongside pembrolizumab, reducing the risk of recurrence or death by 49 percent against immunotherapy alone, a result the chapter says was strong enough to move the combination into phase 3 trials now under way.